NCT04879992 is a NA clinical trial of Esomeprazole in Helicobacter Pylori Infection, sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT04879992?

NCT04879992 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT04879992?

Interventions in NCT04879992: Esomeprazole, Bismuth Potassium Citrate, Tetracycline,Metronidazole, amoxicillin rifabutin.

What condition does NCT04879992 study?

NCT04879992 studies Helicobacter Pylori Infection.

Is NCT04879992 still recruiting?

NCT04879992 is currently completed. Last updated 15 November 2022.

Last reviewed 2022-11-15 · How we verify

NCT04879992

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

Completed NA Last updated 15 November 2022

What this trial tests

NA trial testing Esomeprazole in Helicobacter Pylori Infection in 413 participants. Completed in 30 October 2022.

Timeline

7 May 2021

Primary endpoint
14 October 2022

30 October 2022

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	413
Start date	7 May 2021
Primary completion	14 October 2022
Estimated completion	30 October 2022
Sites	1 location across China

Drugs / interventions tested

Esomeprazole (esomeprazole) — full drug profile →
Bismuth Potassium Citrate — full drug profile →
Tetracycline,Metronidazole — full drug profile →
amoxicillin rifabutin — full drug profile →

Conditions studied

Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 80, any sex, with Helicobacter Pylori Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. Therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treatment of Helicobacter pylori. The purpose of this study was to evaluate the efficacy and safety of rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Chen J, Guo Y, Huang Y, Ding Z, et al · · 2023 · cited 14× · PMID 37079894 · DOI 10.1093/infdis/jiad114

Verify or expand the search:

Other trials of Esomeprazole

Trials testing the same drug.

NCT07399054 — Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU · not yet recruiting
NCT07018635 — A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Adm · Phase 1 · completed
NCT07268820 — Heartburn, Gastroesophageal Reflux Disease · Phase 4 · recruiting
NCT06851468 — Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori · NA · not yet recruiting
NCT06793943 — A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults · Phase 1 · completed

Other recruiting trials for Helicobacter Pylori Infection

Currently open trials in the same condition.

NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
NCT07358130 — Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy · NA · recruiting
NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting
NCT06929962 — VA Dual Sequential Therapy · Phase 4 · recruiting
NCT06959368 — Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication · Phase 4 · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04879992 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 15 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04879992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing